Gofen & Glossberg LLC IL Trims Position in Eli Lilly and Company (LLY)
Gofen & Glossberg LLC IL lessened its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,092 shares of the company’s stock after selling 1,000 shares during the quarter. Gofen & Glossberg LLC IL’s holdings in Eli Lilly and were worth $1,900,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after buying an additional 1,610,885 shares in the last quarter. BlackRock Inc. increased its position in Eli Lilly and by 2.1% in the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after buying an additional 1,323,259 shares in the last quarter. State Street Corp increased its position in Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after buying an additional 651,424 shares in the last quarter. Janus Henderson Group PLC increased its position in Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after buying an additional 9,223,251 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after buying an additional 708,597 shares in the last quarter. Institutional investors own 76.45% of the company’s stock.
Several analysts recently issued reports on LLY shares. Jefferies Group reiterated a “buy” rating and set a $89.00 target price on shares of Eli Lilly and in a research report on Monday, September 11th. BMO Capital Markets reiterated an “underperform” rating and set a $71.00 target price (down previously from $73.00) on shares of Eli Lilly and in a research report on Wednesday, September 6th. Credit Suisse Group cut Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their target price for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Piper Jaffray Companies reiterated an “overweight” rating and set a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Finally, Berenberg Bank reiterated a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. Eli Lilly and currently has an average rating of “Hold” and a consensus price target of $90.25.
In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 772,003 shares of company stock valued at $64,837,441. 0.20% of the stock is owned by corporate insiders.
Shares of Eli Lilly and Company (NYSE:LLY) traded up $0.24 during trading on Wednesday, reaching $85.05. The company had a trading volume of 2,659,400 shares, compared to its average volume of 3,673,559. Eli Lilly and Company has a 52 week low of $65.66 and a 52 week high of $89.09. The company has a market capitalization of $92,525.02, a price-to-earnings ratio of 20.55, a PEG ratio of 1.86 and a beta of 0.34. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period in the prior year, the company earned $0.88 earnings per share. The firm’s revenue was up 9.0% on a year-over-year basis. sell-side analysts predict that Eli Lilly and Company will post 4.21 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is presently 98.58%.
COPYRIGHT VIOLATION NOTICE: “Gofen & Glossberg LLC IL Trims Position in Eli Lilly and Company (LLY)” was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/11/29/gofen-glossberg-llc-il-trims-position-in-eli-lilly-and-company-lly.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.